US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
Medtech IPOs rocketed just as stock markets faltered
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Moderna picks its moment
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Biotech flotations remain in high demand
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Floating device companies stay at home
Nine IPOs have got away so far this year, and one of them is very big indeed.
June rush drives near-record quarter for biotech flotations
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
First-quarter floats hold amid uncertain climate
Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.